Jaguar Health, Inc. (JAGX)
| Market Cap | 1.39M -75.0% |
| Revenue (ttm) | 29.57M +156.0% |
| Net Income | -50.13M |
| EPS | -262.29 |
| Shares Out | 603.13K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,052 |
| Open | 2.560 |
| Previous Close | 2.470 |
| Day's Range | 2.290 - 2.560 |
| 52-Week Range | 2.290 - 125.304 |
| Beta | -0.10 |
| Analysts | Buy |
| Price Target | 262.50 (+11,263.64%) |
| Earnings Date | May 20, 2026 |
About JAGX
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS... [Read more]
Financial Performance
In 2025, Jaguar Health's revenue was $11.51 million, a decrease of -1.52% compared to the previous year's $11.69 million. Losses were -$53.58 million, 39.2% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for JAGX stock is "Buy" and the 12-month stock price target is $262.5.
News
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here Reminder: Two cr...
Jaguar Health Transcript: Emerging Growth Conference 93
A year of transformation is underway, driven by a $38M non-dilutive licensing deal and a strategic focus on rare diseases. Crofelemer’s new formulation shows up to 37% reduction in parenteral support for MVID, with regulatory filings and key data readouts expected within 12 months.
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jagu...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Jaguar Health says research in ethnobotanical medicine helps advance crofelemer
Jaguar Health (JAGX) and family company Napo Pharmaceuticals highlighted how the Company’s long-standing research in ethnobotanical medicine, sustainable harvesting, and regulatory drug development un...
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulat...
Jaguar Health Transcript: Lytham Partners Spring 2026 Investor Conference
A transformative out-license deal is fueling focused R&D on rare intestinal failure diseases, with crofelemer showing strong efficacy and safety in reducing parenteral support for MVID and short bowel syndrome. NDA filing for MVID is targeted for mid-2027.
Jaguar Health regains compliance with Nasdaq Listing Rule
Jaguar Health (JAGX) announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market that Jaguar has regained compliance with Nasdaq Listing Rule 5550(a)(2). Published…
Jaguar Health Compliant with Nasdaq Bid Price Rule
JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on ...
Jaguar Health Earnings Call Transcript: Q1 2026
Net revenue soared 816% year-over-year in Q1 2026, driven by a major out-license deal, while strategic focus shifted to rare disease drug development. Clinical milestones and non-dilutive funding position the company for future growth.
Jaguar Health Quarterly report: Q1 2026
Jaguar Health has published its Q1 2026 quarterly earnings report on May 26, 2026.
Jaguar Health Earnings release: Q1 2026
Jaguar Health released its Q1 2026 earnings on May 26, 2026, summarizing the period's financial results.
Jaguar Health Slides: Corporate presentation
Jaguar Health has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2026.
Jaguar Health reports Q1 EPS ($13.60) vs. ($584.45) last year
Reports Q1 revenue $20.27M vs. $2.21M last year. The company said, “Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025,…
Jaguar Health Reports First Quarter 2026 Financials
Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs.
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners Conference Company plans to file its Earnings Report on May 20, 2026 on Fo...
Jaguar says first patient from pediatric MVID entered active treatment
Jaguar Health (JAGX) announced that the first patient from the cohort of pediatric MVID patients in the pivotal MVID randomized double-blind crossover clinical trial has entered the active treatment o...
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer...
Jaguar Health granted extension to comply with Nasdaq bid price rule
Jaguar Health (JAGX) provided an update on the status of the Company’s listing on The Nasdaq Stock Market. On May 6, 2026, Jaguar received a decision letter from the Nasdaq…
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Ma...
Jaguar Health’s Napo held preliminary discussion with FDA over crofelemer
Jaguar Health (JAGX) family company Napo Pharmaceuticals announced that the company recently held a preliminary discussion with the Division of Gastroenterology at U.S. Food and Drug Administration to...
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on May 6, 2026, providing details for shareholder voting and corporate governance matters.
Jaguar Health announces planned launch of Neonorm Dog
Jaguar Health (JAGX) announced the planned launch of Neonorm Dog, a new extension of the Company’s Neonorm franchise for companion animals. Neonorm Dog is designed to provide dog owners with…
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool formation, gut hydra...